Learn how to find the current needed to deflect a compass needle in this step-by-step physics tutorial! Explore the principles of magnetic fields, current-carrying wires, and the interaction with a ...

Whether you have privacy concerns or you just want to freely tinker, these are our favorite alternatives to stock Android.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

Compass Datacenters, acquired by Brookfield in 2023, is preparing to issue asset-backed securities tied to fully leased data centers in Phoenix and Toronto.

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

Investing.com - Canaccord Genuity raised its price target on Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00 on Wednesday, while maintaining a Buy rating on the stock. The new target ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.